Evotec's Restructuring Plan Faces Market Scrutiny

Evotec surpasses cost-cutting goals and sells a site for $350M, but shares remain weak. Market awaits proof of turnaround by 2028.

Despite making measurable progress on a major corporate overhaul and exceeding its own cost-cutting targets, shares of Hamburg-based drug discovery firm Evotec remain entrenched in a persistent downtrend. The critical question for investors is whether the deep operational cuts and a multi-million dollar asset sale will be sufficient to restore confidence.

The company's recent presentation highlighted tangible advances in its "Priority Reset" initiative. Management has already surpassed the original goal of reducing costs by at least €40 million by 2025. However, this efficiency gain stems from profound cuts, including the elimination of approximately 600 full-time positions in the preclinical development segment by mid-2025. The strategic shift toward a less capital-intensive business model is weighing on near-term sentiment, which helps explain the ongoing share price weakness. Closing at €5.46 last Friday, the stock is down nearly 11% over the past month, trading notably below its 50-day moving average.

Liquidity Boost from Strategic Divestment

A key financial pillar in this transition is the sale of Evotec's biologics site in Toulouse, France, to Sandoz. This transaction immediately provides the company with $350 million in cash. Market observers view this move as a crucial liquidity injection that simultaneously reduces the group's operational execution risk. Looking further ahead, the deal includes potential milestone payments of up to $300 million, plus tiered royalties once the relevant products reach the market.

Concurrently, the company is banking on its internal research pipeline. With over 100 projects in development—more than 60% of which are partnered—Evotec anticipates cumulative cash inflows of up to half a billion dollars by 2028.

April 2026: A Pivotal Date for Validation

These strategic moves support the confirmed medium-term target of achieving an EBITDA margin exceeding 20% by 2028. Whether the market will reward this long-term perspective hinges on an upcoming event scheduled for April 8, 2026. On that date, management will release the annual report and present the outlook for the current year. This presentation represents a critical moment for leadership to substantiate the restructuring's benefits with concrete figures. They must demonstrate how the transformation is stabilizing recently soft revenues in drug discovery and translating into sustainable earnings growth, moving beyond mere cost reduction.